Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HILDEGAZ: Zoledronic Acid and IL-2 After Haplo-SCT
NCT03862833Phase 1Completed
- Sponsor
- CHU de Nantes
- Start
- May 2019
- Primary completion
- Aug 2023
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of aldesleukin and zoledronic acid in hematologic disease (2 arms), sponsored by CHU de Nantes. Primary endpoint: Maximum Tolerated Dose. Started May 2019; status: completed.
02
Drugs
aldesleukinzoledronic acid
03
Conditions
hematologic disease
Beyond the preview
Go deeper on NCT03862833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03862833.